Revive Therapeutics Gets Nod From FDA, Could Conduct Psilocybin Study Trials In 2023

Oral psilocybin film-strips to treat could conduct the first-in-human clinical study as soon as next year.

A life sciences company developing dissolvable, oral psilocybin film-strips to treat could conduct its first-in-human clinical study as soon as next year.

On Friday, Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) gave an update on the company’s Phase I/II clinical study of oral psilocybin to treat mental illness, substance abuse, and neurological disorders.

Prototypes of the oral psilocybin thin film strip product have been developed and are being optimized for use in upcoming IND-enabling studies.

“We intend to advance the development of our oral psilocybin thin film strip product for these indications,” said Derrick Welsh, COO of Psilocin Pharma, a division of Revive.

The company has initiated the product development program under a feasibility agreement with LTS Lohmann Therapie-Systeme AG, which specializes in pharmaceutical oral thin films, to develop and manufacture a proprietary oral psilocybin thin film strip product.

“In parallel, we are working on our first clinical study evaluating oral psilocybin in the treatment of methamphetamine use disorder to validate its use in substance abuse indications,” Welsh added.

The company has been evaluating the use of oral psilocybin as a potential treatment for methamphetamine use disorder with the University of Wisconsin-Madison’s School of Medicine and Public Health and School of Pharmacy.

The Phase I/II clinical study looking at the safety and utility of psilocybin in adults with methamphetamine use disorder received both FDA and Institutional Review Board approval.

The clinical data that is generated from the study will provide proprietary and valuable information on the safety, efficacy, and dosing of oral psilocybin to support future pivotal FDA clinical studies for the company’s proposed oral psilocybin thin film strip product.

In addition, the company will have exclusive access to the intellectual property moat from this study to support development, regulatory and commercial initiatives.

“The clinical data from this study will be used to support late-stage clinical trials with our oral psilocybin thin film strip product,” Welsh said.

Adam Jackson

Adam Jackson covers the cannabis industry for The Green Market Report. He previously covered the Missouri statehouse for The Columbia Missourian and freelanced for The Missouri Independent. He most recently covered retail, restaurants, and other consumer companies for Bloomberg Business News. You can find him on Twitter @adam_sjackson and email him at adam.jackson@crain.com.


Leave a Reply

Your email address will not be published. Required fields are marked *

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 2 days

MSO Halo Collective Closes Pistil Point Acquisition in Oregon

@GreenMarketRpt – 2 days

Michigan Researchers To Study Cannabis Treatments For Chronic Pain

@GreenMarketRpt – 2 days

Las Vegas Council Signs Off on Cannabis Consumption Lounges

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.